Although GR antagonism has been shown to inhibit gluconeogenesis and lower glucose in humans [1] and in rodent model of T2D [23], the concern about GR antagonists on pro-inflammation hampers the long-term treatment with GR antagonists in T2D. Here, NR3C1 is linked to type 2 diabetes mellitus.